Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Get Free Trial
Send Info
Syndicate
PepGen files $300M mixed securities shelf  16:13
06/02/23
06/02
16:13
06/02/23
16:13
PEPG

PepGen

$16.13 /

+1.47 (+10.03%)

 
ShowHide Related Items >><<
PEPG PepGen
$16.13 /

+1.47 (+10.03%)

05/30/23
PepGen announces clinical hold placed on PGN-EDODM1 IND by FDA
05/18/23
PepGen receives NOL for its CTA from Health Canada for Phase 2 CONNECT1-EDO51
05/11/23
PepGen expects cash to fund operations into early 2025
03/22/23
PepGen to hold trials to assess safety and efficacy of repeated PGN-EDO51 doses
PEPG PepGen
$16.13 /

+1.47 (+10.03%)

05/31/23 Wedbush
PepGen clinical hold 'can be overcome,' says Wedbush
03/24/23 Wedbush
PepGen price target raised to $22 from $17 at Wedbush
12/21/22 H.C. Wainwright
PepGen initiated with a Buy at H.C. Wainwright
PEPG PepGen
$16.13 /

+1.47 (+10.03%)

05/11/23
PepGen reports Q1 EPS (69c), consensus (79c)
06/22/23
PepGen, Inc.
Hot Stocks
Neurocrine presents data from long term use of INGREZZA » 08:32
06/02/23
06/02
08:32
06/02/23
08:32
NBIX

Neurocrine

$91.11 /

+1.59 (+1.78%)

Neurocrine Biosciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 5th, 08:32

Get Free Trial

ShowHide Related Items >><<
NBIX Neurocrine
$91.11 /

+1.59 (+1.78%)

05/19/23
Neurocrine: Results from Phase 3 KINECT-HD study published in The Lancet
05/15/23
Neurocrine presents results of Ingrezza capsules in dyskinesia and schizophrenia
05/12/23
Neurocrine to present new analysis of Phase 2 data of crinecerfont in adults
05/03/23
Neurocrine chief HR officer Cooke sells 11,397 common shares
NBIX Neurocrine
$91.11 /

+1.59 (+1.78%)

05/04/23 Canaccord
Neurocrine price target lowered to $130 from $132 at Canaccord
05/04/23 Mizuho
Neurocrine price target lowered to $111 from $116 at Mizuho
05/04/23 Guggenheim
Guggenheim upgrades Neurocrine to Buy on Ingrezza strength, pipeline potential
05/04/23 Citi
Neurocrine price target lowered to $122 from $127 at Citi
NBIX Neurocrine
$91.11 /

+1.59 (+1.78%)

05/03/23
Neurocrine reports Q1 adjusted EPS (51c), consensus 13c
02/06/23
Neurocrine reports Q4 non-GAAP EPS $1.24, consensus $1.14
NBIX Neurocrine
$91.11 /

+1.59 (+1.78%)

05/04/23
What You Missed On Wall Street On Thursday
05/04/23
What You Missed On Wall Street This Morning
05/04/23
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
02/03/23
What You Missed On Wall Street On Friday
08/20/23
PDUFA Date for Valbenazine
Recommendations
Republic Services price target raised to $158 from $154 at Morgan Stanley » 07:53
06/02/23
06/02
07:53
06/02/23
07:53
RSG

Republic Services

$142.73 /

+1.09 (+0.77%)

Morgan Stanley raised the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 5th, 07:53

Get Free Trial

ShowHide Related Items >><<
RSG Republic Services
$142.73 /

+1.09 (+0.77%)

05/02/23
Teamsters ratify new agreement at Republic Services in Alabama
03/31/23
Teamsters says Republic Services workers in Arizona vote to join union
03/27/23
Republic Services acquires North State Bioenergy, terms not disclosed
02/20/23
Fly Intel: Top five weekend stock stories
RSG Republic Services
$142.73 /

+1.09 (+0.77%)

05/01/23 TD Cowen
Republic Services price target raised to $155 from $150 at TD Cowen
04/17/23 Truist
Republic Services initiated with a Hold at Truist
04/17/23 Truist
Republic Services initiated with a Hold at Truist
03/30/23 TD Cowen
Republic Services initiated with a Market Perform at TD Cowen
RSG Republic Services
$142.73 /

+1.09 (+0.77%)

04/27/23
Republic Services reports Q1 adjusted EPS $1.24, consensus $1.13
02/15/23
Republic Services sees FY23 adjusted EPS $5.15-$5.23, consensus $5.04
02/15/23
Republic Services reports Q4 adjusted EPS $1.13, consensus $1.02
RSG Republic Services
$142.73 /

+1.09 (+0.77%)

02/18/23
Waste Management among garbage stocks to buy now, Barron's says
Periodicals
Medicare will cover Biogen, Eisai's Alzheimer's drug, WSJ reports » 06:17
06/02/23
06/02
06:17
06/02/23
06:17
BIIB

Biogen

$302.26 /

+5.94 (+2.00%)

The Centers for Medicare…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return on Jun 5th, 06:17

Get Free Trial

ShowHide Related Items >><<
BIIB Biogen
$302.26 /

+5.94 (+2.00%)

05/22/23
Biogen reports Eisai submitted MAA for lecanemab for early Alzheimer's to MHRA
05/15/23
Canadian Solar subsidiary signs aggregation deal for 100MW in Texas
05/12/23
BiomX appoints Jason Marks, Michael Dambach to board of directors
05/09/23
Vigil Neuroscience appoints Haeberlein to board of directors
BIIB Biogen
$302.26 /

+5.94 (+2.00%)

06/01/23 Piper Sandler
Biogen price target raised to $360 from $346 at Piper Sandler
05/15/23 Morgan Stanley
Eli Lilly price target raised to $507 from $478 at Morgan Stanley
05/11/23 Argus
Biogen price target raised to $350 from $320 at Argus
05/04/23 BMO Capital
Eli Lilly price target raised to $505 from $430 at BMO Capital
BIIB Biogen
$302.26 /

+5.94 (+2.00%)

04/25/23
Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48
04/25/23
Biogen reports Q1 EPS $3.40, consensus $3.28
02/15/23
Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72
02/15/23
Biogen reports Q4 EPS $4.05, consensus $3.48
BIIB Biogen
$302.26 /

+5.94 (+2.00%)

04/11/23
Drugmakers call for abortion pill ruling reversal, Reuters reports
03/13/23
VA to widely cover new Alzheimer's treatment from Eisai and Biogen, STAT says
01/11/23
FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports
12/23/22
Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports
BIIB Biogen
$302.26 /

+5.94 (+2.00%)

05/08/23
Fly Insider: Zions Bancorp, Albertsons among week's notable insider trades
05/05/23
Buy/Sell: Wall Street's top 10 stock calls this week
05/01/23
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
04/27/23
Biotech Alert: Searches spiking for these stocks today
07/06/23
PDUFA Date for Leqembi
08/05/23
PDUFA Date for Zuranolone
06/14/23
Biogen Inc
Thursday
Hot Stocks
Alkermes names Caroline Loew, Ph.D as CEO designate of Mural Oncology » 16:02
06/01/23
06/01
16:02
06/01/23
16:02
ALKS

Alkermes

$29.27 /

+0.365 (+1.26%)

Alkermes announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALKS Alkermes
$29.27 /

+0.365 (+1.26%)

04/26/23
Alkermes making 'meaningful progress' on oncology separation
04/25/23
Alkermes receives second interim award in Janssen arbitration
04/18/23
Alkermes submits Form 10 to SEC for planned separation of oncology business
03/23/23
Alkermes' Lybalvi featured in study published in Journal of Clinical Psychiatry
ALKS Alkermes
$29.27 /

+0.365 (+1.26%)

05/22/23 Piper Sandler
Alkermes positioned for 'meaningful further value creation,' says Piper
04/27/23 Mizuho
Alkermes earnings selloff a buying opportunity, says Mizuho
04/27/23 H.C. Wainwright
Alkermes price target raised to $34 from $32 at H.C. Wainwright
04/26/23 Mizuho
Alkermes arbitration award better than expected, says Mizuho
ALKS Alkermes
$29.27 /

+0.365 (+1.26%)

04/26/23
Alkermes reiterates financial expectations for 2023
04/26/23
Alkermes reports Q1 non-GAAP EPS 1c, consensus (2c)
02/16/23
Alkermes sees FY23 adjusted EPS 0c-23c, consensus 26c
02/16/23
Alkermes reports Q4 adjusted EPS 14c, consensus 5c
ALKS Alkermes
$29.27 /

+0.365 (+1.26%)

04/28/23
Biotech Alert: Searches spiking for these stocks today
06/02/23
2023 ASCO Annual Meeting
Recommendations
Biogen price target raised to $360 from $346 at Piper Sandler » 08:32
06/01/23
06/01
08:32
06/01/23
08:32
BIIB

Biogen

$296.21 /

-2.3 (-0.77%)

Piper Sandler raised the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BIIB Biogen
$296.21 /

-2.3 (-0.77%)

05/22/23
Biogen reports Eisai submitted MAA for lecanemab for early Alzheimer's to MHRA
05/15/23
Canadian Solar subsidiary signs aggregation deal for 100MW in Texas
05/12/23
BiomX appoints Jason Marks, Michael Dambach to board of directors
05/09/23
Vigil Neuroscience appoints Haeberlein to board of directors
BIIB Biogen
$296.21 /

-2.3 (-0.77%)

05/15/23 Morgan Stanley
Eli Lilly price target raised to $507 from $478 at Morgan Stanley
05/11/23 Argus
Biogen price target raised to $350 from $320 at Argus
05/04/23 BMO Capital
Eli Lilly price target raised to $505 from $430 at BMO Capital
BIIB Biogen
$296.21 /

-2.3 (-0.77%)

04/25/23
Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48
04/25/23
Biogen reports Q1 EPS $3.40, consensus $3.28
02/15/23
Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72
02/15/23
Biogen reports Q4 EPS $4.05, consensus $3.48
BIIB Biogen
$296.21 /

-2.3 (-0.77%)

04/11/23
Drugmakers call for abortion pill ruling reversal, Reuters reports
03/13/23
VA to widely cover new Alzheimer's treatment from Eisai and Biogen, STAT says
01/11/23
FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports
12/23/22
Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports
BIIB Biogen
$296.21 /

-2.3 (-0.77%)

05/08/23
Fly Insider: Zions Bancorp, Albertsons among week's notable insider trades
05/05/23
Buy/Sell: Wall Street's top 10 stock calls this week
05/01/23
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
04/27/23
Biotech Alert: Searches spiking for these stocks today
07/06/23
PDUFA Date for Leqembi
08/05/23
PDUFA Date for Zuranolone
06/14/23
Biogen Inc
Hot Stocks
Ionis Pharmaceuticals reports 'positive' clinical progress with donidalorsen » 07:16
06/01/23
06/01
07:16
06/01/23
07:16
IONS

Ionis Pharmaceuticals

$40.89 /

+0.3399 (+0.84%)

Ionis Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$40.89 /

+0.3399 (+0.84%)

05/16/23
Chinook Therapeutics enters partnership with Ionis Pharmaceuticals
04/25/23
FDA approves Ionis Pharma/Biogen's QALSODY as first treatment in ALS
04/25/23
Biogen confirms FDA grants accelerated approval for Qalsody
04/24/23
AstraZeneca, Ionis announce eplontersen trial met all endpoints
IONS Ionis Pharmaceuticals
$40.89 /

+0.3399 (+0.84%)

05/04/23 Citi
Ionis Pharmaceuticals upgraded to Neutral from Sell at Citi
05/04/23 Barclays
Ionis Pharmaceuticals price target lowered to $37 from $40 at Barclays
04/20/23 Guggenheim
Guggenheim previews Ionis' Eplontersen ATTR-PN update at AAN
03/21/23 Bernstein
Ionis Pharmaceuticals initiated with an Underperform at Bernstein
IONS Ionis Pharmaceuticals
$40.89 /

+0.3399 (+0.84%)

05/03/23
Ionis Pharmaceuticals reports Q1 EPS (87c), consensus (91c)
02/22/23
Ionis Pharmaceuticals sees FY23 revenue $575M, consensus $672.18M
02/22/23
Ionis Pharmaceuticals reports Q4 EPS (37c), consensus (92c)
IONS Ionis Pharmaceuticals
$40.89 /

+0.3399 (+0.84%)

05/04/23
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
04/27/23
Biotech Alert: Searches spiking for these stocks today
03/24/23
Buy/Sell: Wall Street's top 10 stock calls this week
03/21/23
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
12/22/23
PDUFA Date for Eplontersen
06/01/23
Ionis Pharmaceuticals Inc
Wednesday
Recommendations
PepGen clinical hold 'can be overcome,' says Wedbush » 07:56
05/31/23
05/31
07:56
05/31/23
07:56
PEPG

PepGen

$15.60 /

+0.03 (+0.19%)

Wedbush keeps an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 04:36:24

Get Free Trial

ShowHide Related Items >><<
PEPG PepGen
$15.60 /

+0.03 (+0.19%)

05/30/23
PepGen announces clinical hold placed on PGN-EDODM1 IND by FDA
05/18/23
PepGen receives NOL for its CTA from Health Canada for Phase 2 CONNECT1-EDO51
05/11/23
PepGen expects cash to fund operations into early 2025
03/22/23
PepGen to hold trials to assess safety and efficacy of repeated PGN-EDO51 doses
PEPG PepGen
$15.60 /

+0.03 (+0.19%)

03/24/23 Wedbush
PepGen price target raised to $22 from $17 at Wedbush
12/21/22 H.C. Wainwright
PepGen initiated with a Buy at H.C. Wainwright
PEPG PepGen
$15.60 /

+0.03 (+0.19%)

05/11/23
PepGen reports Q1 EPS (69c), consensus (79c)
06/22/23
PepGen, Inc.
Recommendations
Amylyx negative CHMP opinion 'not a major surprise,' says BofA » 07:28
05/31/23
05/31
07:28
05/31/23
07:28
AMLX

Amylyx

$24.03 /

-0.79 (-3.18%)

After Amylyx announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 04:08:5

Get Free Trial

ShowHide Related Items >><<
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/30/23
Amylyx informed that CHMP is trending toward a negative opinion on AMX0035 MAA
04/13/23
Amylyx: First person dosed in AMX0035 trial for Wolfram Syndrome treatment
02/02/23
Amylyx completes enrollment in global Phase 3 trial of AMX0035 in ALS
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/31/23 Mizuho
Amylyx can still win approval in Europe, says Mizuho
05/15/23 Mizuho
Amylyx price target lowered to $50 from $52 at Mizuho
03/30/23 Mizuho
Amylyx initiated with a Buy at Mizuho
03/14/23 Citi
Amylyx price target raised to $54 from $51 at Citi
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/11/23
Amylyx reports Q1 EPS 2c, consensus (24c)
03/13/23
Amylyx reports Q4 EPS (65c), consensus (82c)
  • 07
    Oct
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/12/23
Fly Intel: Pre-market Movers
05/11/23
Fly Intel: After-Hours Movers
03/14/23
What You Missed On Wall Street On Tuesday
03/14/23
What You Missed On Wall Street This Morning
06/08/23
Amylyx Pharmaceuticals, Inc.
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

03/13/23
Amylyx Pharmaceuticals options imply 16.5% move in share price post-earnings
Recommendations
Amylyx can still win approval in Europe, says Mizuho » 07:02
05/31/23
05/31
07:02
05/31/23
07:02
AMLX

Amylyx

$24.03 /

-0.79 (-3.18%)

Mizuho analyst Graig…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 03:42:3

Get Free Trial

ShowHide Related Items >><<
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/30/23
Amylyx informed that CHMP is trending toward a negative opinion on AMX0035 MAA
04/13/23
Amylyx: First person dosed in AMX0035 trial for Wolfram Syndrome treatment
02/02/23
Amylyx completes enrollment in global Phase 3 trial of AMX0035 in ALS
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/15/23 Mizuho
Amylyx price target lowered to $50 from $52 at Mizuho
03/30/23 Mizuho
Amylyx initiated with a Buy at Mizuho
03/14/23 Citi
Amylyx price target raised to $54 from $51 at Citi
01/05/23 BofA
BofA starts Amylyx with a Buy given 'huge unmet need' in ALS
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/11/23
Amylyx reports Q1 EPS 2c, consensus (24c)
03/13/23
Amylyx reports Q4 EPS (65c), consensus (82c)
  • 07
    Oct
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

05/12/23
Fly Intel: Pre-market Movers
05/11/23
Fly Intel: After-Hours Movers
03/14/23
What You Missed On Wall Street On Tuesday
03/14/23
What You Missed On Wall Street This Morning
06/08/23
Amylyx Pharmaceuticals, Inc.
AMLX Amylyx
$24.03 /

-0.79 (-3.18%)

03/13/23
Amylyx Pharmaceuticals options imply 16.5% move in share price post-earnings

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.